Heard the call (all 10 minutes of it, 1/4 is safe harbor :-)) said drug performed as expected... the dread control arm much better than any past study or any data that they're aware of.
88 million cash at end of December burn 4-5m per month. Doing controlled shut down of the program and already laying off staff. Only other program is preclinical. They have 17+m debt though and from the K looks like 30+m shares. Probably should be a reverse merger but not a big enough discount to cash (for me) to speculate especially since don't know if management will try to keep things (their jobs) going a bit longer.
Market Data 
Markets 
AI
